1643-P: Unique Signature of Circular RNA in Skeletal Muscle of Different Insulin Sensitivity

Abstract

Diabetes pathologies are complex, affecting numerous organs such as liver, pancreas, and skeletal muscle. Circular RNAs (circRNA) are a class of non-coding RNAs that are characterized by a covalently closed loop structure. Functionally, they can act on cell physiology by sponging microRNAs and thus regulating gene and protein expression. The emerging function of these circRNA is not fully understood, but initial studies have recently shown that circRNA are involved in insulin secretion regulation. Therefore, deregulation of this class of RNAs may lead to metabolic disorders in pancreatic β-cells and thus be involved in the pathogenesis of type 1 (T1DM) and type 2 diabetes (T2DM). Our research is focused on the unique signature by circular RNA and the impact on skeletal muscle metabolism. We demonstrated that human skeletal muscle cells in culture maintain their gene expression phenotype. A different gene signature of the cells according to their different muscular fiber type sources (oxidative versus glycolytic versus mixt) was confirmed. Moreover, an independent microRNA composition has also been highlighted. As CircRNA can regulate microRNAs and then gene expression and proteins, we wondered whether these observed signatures could be explained by circRNA. We therefore focused on key circRNAs involved in myogenesis (such as circZNF609, circHIPK3) and we were able to see that there is a difference in expression of circRNA according to the muscle type. Moreover, we analyzed correlations between circRNA levels and insulin sensitivity (measured by PKB phosphorylation). Finally, we are currently completing our analysis with in-depth sequencing techniques to identify all expressed circRNA in muscle fiber types to potentially identify new targets in insulin metabolic pathways. Disclosure M.Yepmo: None. E.Meugnier: None. M.Pinget: Consultant; Novo Nordisk, Stock/Shareholder; ILONOV. K.Bouzakri: Consultant; Adocia, Stock/Shareholder; ILONOV.